The BBCIC: Governance and Scientific Operation of a Multi-stakeholder Scientific Research Consortium

Charles E. Barr, MD, MPH
Chief Science Officer
Biologics Biosimilars Collective Intelligence Consortium (BBCIC)
AMCP BBCIC, LLC
Disclaimer – Content Slide

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners.
Disclosures

- **Charlie Barr** is a **current employee** of the AMCP BBCIC, LLC

- **Former employee** of Genentech, Roche, Pfizer, Pharmacia and others

- **Financial**: Stock in Roche/Genentech, mutual funds
Agenda 9:00 to 10:15am

- **Charlie Barr**, Chief Science Officer, BBCIC
  - Governance and Scientific Operation of a Research Consortium (10 min)

- **Kevin Haynes**, Director of Clinical Epidemiology, HealthCore
  - Payer contributions to biosimilar safety surveillance (16 min)

- **Nancy Lin**, Senior Scientist, Optum Epidemiology
  - Research challenges in biosimilar safety and surveillance (16-18 min)

- **Hillel Cohen**, Executive Director Scientific Affairs, Sandoz
  - Pharmaceutical industry experience with biosimilar postmarketing safety (18-20 min)

- **Discussion and Q&A** (10-15 min)
Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)

- Multi-stakeholder, non-profit, scientific public service initiative that will monitor biosimilars and corresponding novel biologics for effectiveness and safety

**Mission:** To provide a range of research services that support the following value propositions

- Address important questions about the use, impact, safety, and clinical effectiveness of biologics and biosimilars on human health.
- Increase the rigor and credibility of real world evidence
- Provide access to a large population for epidemiologic studies and health services research
- Improve the efficiency and cost-effectiveness of post-marketed observational studies
- Develop standard approaches to common data needs and address gaps in tools and methods

www.bbcic.org
BBCIC Governance

Public representatives:
- ASCO CancerLinQ (Miller)
- American College of Rheumatology (Curtis)
- National Health Council (Perfetto)
Stakeholders play an active and extensive role

Focus on biologic class and diseases for new biosimilars

Descriptive analysis
– To understand patients, disease, treatments, outcomes
– To understand data, methods, gaps, possible solutions

Comparative analysis
– Both safety and effectiveness
– All biosimilars for originator biologic

Active surveillance

Leverage Sentinel
BBCIC Scientific Operations

Disease and Biologic Products (Research Teams)

Part 1. Descriptive Studies
- ESAs
- GCSF
- Insulins
- Anti-Inflammatory agents

Part 2. Hypothesis-driven Comparative Safety and Effectiveness Studies

Data & Infrastructure Study Design & Analytic Methods (Work Groups)

Gaps

Solutions

Data Availability & Characterization
- Capture of NDC on medical claims
- Impact of ICD-9 to ICD-10 transition and algorithms for mapping

Study Design & Methods
- Switching study design & analytic approaches (anti-inflammatories)
- Comparative safety & effectiveness study design & analytic approaches (insulins)
Three articles published jointly in 2017:

- *Pharmacoepidemiology and Drug Safety*
- *Value in Health*

- Greenfield S. Making RWE more useful for **decision making**.

ISPOR: International Society of Pharmacoeconomics and Outcomes Research
ISPE: International Society of Pharmacoepidemiology
7 Recommendations of Joint ISPOR/ISPE Task Force:

- **Define study** (questions and purpose)
  - *Exploratory*
  - *Hypothesis evaluating treatment effectiveness* (HETE)

- **Public posting of study protocol** and **analysis plan**

- **Publish study results** (or post on website)

- **Enable replication** (same data and analyses)

- **Confirm important findings** (2nd data source & population)

- **Publicly address methodologic criticism** after publication

- **Include key stakeholders** in design, conduct & dissemination

Berger ML, Sox H, Willke RJ et al. *Value in Health* 2017;20:1001-8
“…RCT* data are also increasingly being seen as problematic not only because of
• the [high] costs,
• the [short] length of the studies, and
• the exclusion of major segments of the population
but also because of the controversies surrounding RCT interpretation.”

“Real-world evidence (RWE) holds enormous promise, with some of that promise beginning to be realized in the evaluation of harms.

However, in order to accomplish major strides in harms assessment, and ultimately in the evaluation of effectiveness, many steps have to be taken…”

Sheldon Greenfield, MD. Making real-world evidence more useful to decision making. *Value in Health* 2017;20:1023-4
Advancing the science of real-world evidence

| “The ISPOR paper lays out the potentially solvable barriers in its general recommendations. The recommendations are parsimonious and refer to the companion paper by developed by ISPE…on the transparency needed for reproducibility.” |
| “The goal is praiseworthy because of the aspiration to be able to draw ‘causal conclusions’ in combination with experimental studies [RCTs]…” |
| “Multiple converging sub-studies from the same populations, or independent studies combining multiple data sources, could bring real-world data closer to ‘causality’ and could be perceived as acceptable alternatives to randomized trials.” |

Sheldon Greenfield, MD. Making real-world evidence more useful to decision making. *Value in Health* 2017;20:1023-4
Using the best available evidence

• “Many questions about a drug remain unanswered at the time of approval”
• “It is not feasible to answer all of these questions with traditional RCTs.”
• “The FDA uses RWE for regulatory decisions, albeit primarily related to safety. Nevertheless, for some drugs, the demonstration of efficacy has been based on RWE from case series or registries.”

Jonathan P. Jarow, Lisa LaVange, Janet Woodcock.
To show this poll

1. Install the app from pollev.com/app
2. Start the presentation

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
To show this poll

1. Install the app from pollev.com/app
2. Start the presentation

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
To show this poll

1. Install the app from pollev.com/app
2. Start the presentation

Still not working? Get help at pollev.com/app/help
or
Open poll in your web browser
To show this poll

1. Install the app from pollev.com/app
2. Start the presentation

Still not working? Get help at pollev.com/app/help or Open poll in your web browser
To show this poll

1. Install the app from pollev.com/app
2. Start the presentation

Still not working? Get help at pollev.com/app/help or
Open poll in your web browser
Thank You

Charles E. Barr, MD, MPH
Chief Science Officer
AMCP BBCIC, LLC

cbarr@bbcic.org
703-684-2657 office
650-534-6368 cell

Join the conversation #DIA2018